PSIL250516P15000
- 0.00
- 0.000.00%
ADVISORSHARES PSYCHEDELICS ETF Newsroom
Uncovering Potential: NRX Pharmaceuticals's Earnings Preview
ATAI Life Sciences Q1 EPS $(0.15) Beats $(0.18) Estimate, Sales $1.55M
Compass Pathways Analyst Ratings
Trump Says Prescription Drug Prices Set To Drop By 30% To 80% 'Almost Immediately' Thanks To 'Most Favored Nation' Plan, Mark Cuban Urges President To 'Force Transparency'
Chardan Capital Maintains Buy on Mind Medicine, Maintains $20 Price Target
Mind Medicine Analyst Ratings
MindMed Projects 2026 Trial Readouts for Pivotal MM120 Studies in GAD and MDD
Mind Medicine Q1 EPS $(0.35) Beats $(0.38) Estimate
Here Are the Major Earnings Before the Open Tomorrow
COMPASS Pathways ADS Q1 2025 Earnings Preview
Earnings Call Summary | Neuronetics(STIM.US) Q1 2025 Earnings Conference
Neuronetics Shares Are Trading Lower After the Company Reported a Q1 EPS Miss.
Earnings Scheduled For May 6, 2025
NRx Pharmaceuticals Files Patent Application For NRX-100 Formulation Of IV Ketamine
RBC Capital Maintains Sector Perform on Alkermes, Raises Price Target to $40
Earnings Call Summary | Alkermes(ALKS.US) Q1 2025 Earnings Conference
Alks Outlines 2025 Growth With $320M-$340M LYBALVI Sales Target and Key ALKS 2680 Data Milestones
Alkermes Shares Are Trading Higher After the Company Reported Q1 Financial Results and Beat Its EPS and Revenue Estimates.
Alkermes GAAP EPS of $0.13 Beats by $0.08, Revenue of $306.5M Beats by $2.39M
Earnings Scheduled For May 1, 2025